HeartMate PHP™ CE Mark Clinical Investigation Plan

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
High Risk Percutaneous Coronary Intervention
Interventions
DEVICE

Percutaneous ventricular support with the HeartMate PHP

The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,

Trial Locations (7)

Unknown

Instituto del Corazon, Bucaramanga

Sanatorio Italiano, Asunción

3000 CA

Erasmus Medical Center, Rotterdam

40-635

Samodzielny Publiczny Szpital (The Prof. Leszka Gieca Upper-Silesian Medical Centre), Katowice

31-202

University Hospital in Krakow (John Paul II), Krakow

04-628

The Cardinal Stefan Wyszynski Institute of Cardiology, Warsaw

41-800

Slaskie Centrum Chorob Serca w Zabrzu (Silesian Center for Heart Disease), Zabrze

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY

NCT02156609 - HeartMate PHP™ CE Mark Clinical Investigation Plan | Biotech Hunter | Biotech Hunter